<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author><author><style face="normal" font="default" size="100%">Orlowski, R.Z.</style></author><author><style face="normal" font="default" size="100%">Facon, T.</style></author><author><style face="normal" font="default" size="100%">Sonneveld, P.</style></author><author><style face="normal" font="default" size="100%">Anderson, K.C.</style></author><author><style face="normal" font="default" size="100%">Beksac, M.</style></author><author><style face="normal" font="default" size="100%">Benboubker, L.</style></author><author><style face="normal" font="default" size="100%">Roddie, H.</style></author><author><style face="normal" font="default" size="100%">Potamianou, A.</style></author><author><style face="normal" font="default" size="100%">Couturier, C.</style></author><author><style face="normal" font="default" size="100%">Ataman, O.</style></author><author><style face="normal" font="default" size="100%">Ataman, O.</style></author><author><style face="normal" font="default" size="100%">van de Velde, H.</style></author><author><style face="normal" font="default" size="100%">Richardson, P.G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma</style></title><secondary-title><style face="normal" font="default" size="100%">Haematologica</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84920168620&amp;doi=10.3324%2fhaematol.2014.112037&amp;partnerID=40&amp;md5=001d25f00b7ea3c414eb6ecdab6c9648</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">100</style></volume><pages><style face="normal" font="default" size="100%">100 - 106</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Bortezomib-dexamethasone is widely used for relapsed myeloma in routine clinical practice, but comparative data versus single-agent bortezomib are lacking. This retrospective analysis compared second-line treatment with bortezomib- dexamethasone and bortezomib using 109 propensity score-matched pairs of patients treated in three clinical trials: MMY-2045, APEX, and DOXIL-MMY-3001. Propensity scores were estimated using logistic regression analyses incorporating 13 clinical variables related to drug exposure or clinical outcome. Patients received intravenous bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11, in 21-day cycles, alone or with oral dexamethasone 20 mg on the days of/after bortezomib dosing. Median bortezomib cumulative dose (27.02 and 28.60 mg/m2) and treatment duration (19.6 and 17.6 weeks) were similar with bortezomib-dexamethasone and bortezomib, respectively. The overall response rate was higher (75% vs. 41%; odds ratio=3.467; P&lt;0.001), and median time-to-progression (13.6 vs. 7.0 months; hazard ratio [HR]=0.394; P=0.003) and progression-free survival (11.9 vs. 6.4 months; HR=0.595; P=0.051) were longer with bortezomib-dexamethasone versus bortezomib, respectively. Rates of anygrade adverse events, most common grade 3 or higher adverse events, and discontinuations due to adverse events appeared similar between the groups. Two patients per group died of treatment-related adverse events. These data indicate the potential benefit of bortezomib-dexamethasone compared with single-agent bortezomib at first relapse in myeloma. The MMY-2045, APEX, and DOXIL-MMY-3001 clinical trials were registered at, respectively, clinicaltrials.gov identifier: 00908232, 00048230, and 00103506. ©2014 Ferrata Storti Foundation.</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><notes><style face="normal" font="default" size="100%">Cited By :6Export Date: 21 February 2017</style></notes></record></records></xml>